BioSpace News Archive

Skye Bioscience, Inc. announced that it has completed a good laboratory practice (GLP) nonclinical toxicology study of its SBI-100.

Perimeter Medical Imaging AI, Inc. (TSX-V:PINK)(OTC:PYNKF) (FSE:4PC) (“Perimeter” or the “Company”), announced that the Company will issue a news release providing a corporate update followed by a conference call and webcast to be hosted by Jeremy Sobotta, Perimeter’s Chief Executive Officer, at 5 pm Eastern Time on Wednesday February 23, 2022.

Electromed, Inc. today announced the appointment of Christopher Holland as Chief Commercial Officer.

Organon announced that it has acquired the rights from Bayer AG to Marvelon® and Mercilon®, combined oral hormonal daily contraceptive pills, in the People’s Republic of China, including Hong Kong and Macau, and has entered into an agreement to acquire the rights to these products in Vietnam.

Predicine, a global molecular insights company, announced today that it will present six posters highlighting clinical utility of Predicine’s full suite of liquid- and tissue-based comprehensive genomic profiling solutions at the ASCO Genitourinary Cancers Symposium being held February 17-19, 2022, in San Francisco.

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced the execution of territory exclusive distribution agreements in Norway, Finland, and Türkiye.

enVVeno Medical Corporation, a company setting new standards of care for the treatment of venous disease, announced it has received ISO 13485:2016 certification for the Company’s Quality Management System and its manufacturing facility located in Irvine, California.

ImmunoScape, today announced that it has signed a licensing deal with Pure MHC, LLC, a target discovery and development company, to pursue TCR-T therapeutics against Pure MHC-identified antigens in lung cancer, colorectal cancer, and other cancer indications.

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced the closing of its previously announced registered direct offering, whereby a single accredited institutional investor purchased approximately $10 million of the Company’s common stock and pre-funded warrants, as well as warrants to purchase common stock in a concurrent private placement.

Bayer announced today the advancement of key innovation projects that showcase the latest in crop protection, seeds & traits and digital solutions.